arrow
A

Arnulf Stenzl

eberhard karls university of tubingen
H指数:87
被引数:3.6万
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Communication, teamwork, and the role of non-technical skills in Urology: A review by the European School of Urology

沟通、团队合作以及非技术技能在泌尿外科学中的作用:欧洲泌尿外科学会的综述

2025-10-011
OAAI
Reply to the Letter to the Editor Larcher et al. The opera trial: the active role of the patient in the clinical decision-making process and surgical planning (ANNONC-D-25-00583R1)

回复《致编辑函》Larcher et al. 文章:OPERA试验:患者在临床决策过程和手术规划中的积极作用(ANNONC-D-25-00583R1)

2025-09-270
PRE
Using Artificial Intelligence for Text Screening in a Systematic Review of Cardiotoxicity

利用人工智能进行心脏毒性系统评价的文本筛选

2025-09-270
PREAI
Long-term Results from the LEA Randomized Trial: Extended Versus Standard Lymph Node Dissection in Patients with Bladder Cancer Undergoing Radical Cystectomy

LEA随机试验的长期结果:接受根治性膀胱切除术的膀胱癌患者行扩大淋巴结清扫与标准淋巴结清扫的比较

2025-09-170
PRE
Open versus robotic-assisted partial nephrectomy in patients with intermediate/high-complexity kidney tumours: final results of the randomised, controlled, open-label, multicentre trial OpeRa

开放手术与机器人辅助部分肾切除术在中等/高复杂性肾肿瘤患者中的应用比较:随机、对照、开放标签、多中心试验OpeRa的最终结果

2025-04-160
OAAI
The Cost of Bladder Cancer: What Can Be Done?

膀胱癌的成本:我们能做些什么?

2025-01-010
PRE
Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in Oncology
2024-12-010
OAAI
Manfred Wirth - A life devoted to urology in a time of change
2024-10-010
PRE
The Future of Urology: From Carbon Footprint to Artificial Intelligence
2024-09-010
PRE
HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
2024-08-012
OAAI
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis

恩扎鲁他胺治疗年龄 <75岁和 ≥ 75岁的转移性激素敏感性前列腺癌的临床结果: ARCHES事后分析

2024-08-011
OA
Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023?
2024-06-014
OA
Gross Hematuria Associated with Anticoagulants and Antiplatelet Drugs: Analysis of Current Treatment Standards and Relevance of Co-medication and Pharmacological Interactions
2024-05-010
PRE
Xenogenic Application of Human Placenta-Derived Mesenchymal Stromal Cells in a Porcine Large Animal Model
2024-02-074
OAAI
Differentiation of bladder cancer with water flow elastography (WaFE)

应用水流弹性成像 (WaFE) 鉴别膀胱癌

2024-02-011
OAAI
Production of Proliferation- and Differentiation-Competent Porcine Myoblasts for Preclinical Studies in a Porcine Large Animal Model of Muscular Insufficiency
2024-01-310
OAAI
Cell Therapy by Mesenchymal Stromal Cells Versus Myoblasts in a Pig Model of Urinary Incontinence
2024-01-012
PRE
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification

基于TOFIMS质谱的免疫抗体优化肿瘤抗原鉴定

2023-11-177
OAAI
Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty
2023-10-0114
OA
Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study
2023-10-012
OA